Research & Development Committee: Michael Vasconcelles, Gwen Fyfe, Vito Palombella
Nomination & Compensation Committee: William Burns, Steven Holtzman, Michael Vasconcelles
Audit & Finance Committee: Sandip Kapadia, William Burns, Steven Holtzman
We are pioneers: inventors and developers of an entirely new class of therapies.
As our name indicates, collaboration is in our DNA: within our team, with our partners, and with patients and providers. Only by building on deep trust, individual diversity and shared passion can we reach our common goal of surmounting cancer’s toughest challenges.
Our DARPin® platform also embodies this philosophy. Our drug candidates are based on teams of individual DARPins® working together toward one therapeutic goal.
Our long-term strategy matches in-house design and development expertise with world-class partners to deliver a broad pipeline of innovative therapies.
Research & Development Committee: Michael Vasconcelles, Gwen Fyfe, Vito Palombella
Nomination & Compensation Committee: William Burns, Steven Holtzman, Michael Vasconcelles
Audit & Finance Committee: Sandip Kapadia, William Burns, Steven Holtzman